- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT07449702
판상 건선 환자를 대상으로 한 ORKA-001의 개방형 연장 연구
ORKA-001을 사용한 중등도에서 중증의 판상 건선 환자에서 장기간 안전성, 내약성 및 효능을 평가하는 개방형 연장 연구
An open-label extension (OLE) study to evaluate the long-term safety and efficacy of ORKA-001 in adult participants with moderate-to-severe plaque psoriasis, who previously participated in an Oruka Therapeutics sponsored study.
연구 개요
상세 설명
This open-label extension study evaluates the long-term safety and efficacy of ORKA-001 in adults with moderate-to-severe plaque psoriasis. The study includes an open-label treatment period of up to approximately 96 weeks and a post-treatment follow-up period of approximately 48 weeks following the last study visit.
연구 유형
등록 (추정된)
단계
- 2 단계
연락처 및 위치
연구 연락처
- 이름: Oruka Clinical Trials Information
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
연구 장소
-
-
Arizona
-
Phoenix, Arizona, 미국, 85032
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Arkansas
-
North Little Rock, Arkansas, 미국, 72117
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
California
-
Fountain Valley, California, 미국, 92708
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Los Angeles, California, 미국, 90045
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Los Angeles, California, 미국, 90095
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
San Diego, California, 미국, 92123
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Santa Ana, California, 미국, 92701
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Santa Monica, California, 미국, 90403
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Connecticut
-
Cromwell, Connecticut, 미국, 06416
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Florida
-
Miami, Florida, 미국, 33126
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Illinois
-
Rolling Meadows, Illinois, 미국, 60008
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Indiana
-
Plainfield, Indiana, 미국, 46168
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Kentucky
-
Bowling Green, Kentucky, 미국, 42104
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 이메일: clinicaltrials@orukatx.com
-
-
Maryland
-
Rockville, Maryland, 미국, 20850
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02111
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Michigan
-
Detroit, Michigan, 미국, 48202
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
New York
-
New York, New York, 미국, 10023
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
New York, New York, 미국, 10029
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Ohio
-
Cleveland, Ohio, 미국, 44106
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Mason, Ohio, 미국, 45040
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Oregon
-
Portland, Oregon, 미국, 97201
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Portland, Oregon, 미국, 97210
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Texas
-
Frisco, Texas, 미국, 75033
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Houston, Texas, 미국, 77004
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Webster, Texas, 미국, 77598
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Virginia
-
Norfolk, Virginia, 미국, 23502
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
-
-
Alberta
-
Edmonton, Alberta, 캐나다, T5J 3S9
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Edmonton, Alberta, 캐나다, T6G 1C3
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
British Columbia
-
Surrey, British Columbia, 캐나다, V3R 6A7
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Surrey, British Columbia, 캐나다, V3V 0C6
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
New Brunswick
-
Fredericton, New Brunswick, 캐나다, E3B IG9
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Ontario
-
Ajax, Ontario, 캐나다, L1S7K8
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
London, Ontario, 캐나다, N6H 5L5
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Markham, Ontario, 캐나다, L3P 1X3
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Peterborough, Ontario, 캐나다, K9J 5K2
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Toronto, Ontario, 캐나다, M4W 2N4
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Waterloo, Ontario, 캐나다, N2J 1C4
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
Quebec
-
Montreal, Quebec, 캐나다, H2X2V1
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
Québec, Quebec, 캐나다, G1V4X7
- 모병
- Oruka Therapeutics Investigative Site
-
연락하다:
- Oruka Therapeutics Investigative Site
- 전화번호: 781-560-0299
- 이메일: clinicaltrials@orukatx.com
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Signed informed consent by participants from previous trial choosing to transition into the OLE.
- Participants who have successfully completed the preceding trial.
- For women of childbearing potential, must have a negative urine pregnancy test at Baseline visit.
- For women of childbearing potential and fertile male participants with a partner of childbearing potential must be willing to continue to use highly effective contraception
Exclusion Criteria:
- Participants who experienced any adverse events with ORKA-001 in the preceding trial that led to permanent investigational medicinal product discontinuation or, in the opinion of the Investigator, would preclude continued treatment with ORKA-001
- Participants who have developed guttate, erythrodermic or pustular psoriasis or drug-induced psoriasis (as diagnosed by the Investigator), during the preceding trial.
- Evidence of current or previous clinically significant disease, medical condition other than psoriasis, or finding during the medical examination that, in the opinion of the Investigator would compromise the safety of the participant or the quality of the data.
- Any clinically significant laboratory abnormality based on the last available lab results received during the preceding trial, that, according to the Investigator's medical assessment, precludes them from continued treatment with ORKA-001.
- Participant is pregnant or breastfeeding.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: ORKA-001 Once Yearly (High Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
실험적: ORKA-001 Once Yearly (Low Dose)
Participants will receive ORKA-001 once a year per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
실험적: ORKA-001 Twice Yearly
Participants will receive ORKA-001 every 6 months per OLE protocol. |
ORKA-001 administered by subcutaneous (SC) injection |
|
간섭 없음: No Drug
Participants will receive no drug until protocol defined PASI response criterion is met. |
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Incidence of Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events (TESAEs), and TEAEs of Special Interest (TEAESIs)
기간: Day 1 through Week 144
|
Incidence of treatment adverse events, treatment-emergent serious adverse events, treatment adverse events of special interest, and potential clinically significant changes from baseline in vital signs, clinical laboratory parameters and electrocardiograms. |
Day 1 through Week 144
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Proportion of Participants Maintaining PASI100 in the Subset of Participants Meeting the Criterion at Baseline of OLE
기간: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining PASI90 in the Subset of Participants Meeting the Criterion at Baseline of OLE
기간: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0 in the Subset of Participants Meeting the Criterion at Baseline of OLE
기간: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
|
Proportion of Participants Maintaining Investigator's Global Assessment (IGA) 0/1 in the Subset of Participants Meeting the Criterion at Baseline of OLE
기간: Time Frame: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Time Frame: Day 1 through Week 96
|
|
Proportion of Participants with an Improvement of their OLE Baseline PASI Score in the Subset of Participants who did not Achieve PASI75 at OLE Baseline
기간: Day 1 through Week 96
|
Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI100 in the Subset of Participants who achieved PASI100 at Baseline of OLE
기간: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
Time-to-loss of PASI90 in the Subset of Participants who achieved PASI90 at Baseline of the OLE
기간: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
PASI Score Over Time
기간: Day 1 through Week 96
|
The Psoriasis Area and Severity Index Score (PASI) is an evaluation tool that combines the assessment of the severity and the area affected by psoriasis into a single score ranging from 0 (no disease) to 72 (maximum disease). |
Day 1 through Week 96
|
|
IGA Score Over Time
기간: Day 1 through Week 96
|
The Investigator Global Assessment (IGA) documents the Investigator's assessment of the participant's psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as clear (0), almost clear (1), mild (2), moderate (3), or severe (4). |
Day 1 through Week 96
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .